The learning objectives of this program are:
- Identify which patients are most likely to benefit from PCSK9 inhibition for the treatment of hypercholesterolemia.
- Evaluate recent efficacy and safety data and for the use of PCSK9 inhibitors for CVRR in patients not achieving lipid treatment goals
- Apply treatment strategies to individual care plans for patients at cardiovascular risk needing additional lipid reduction
- Discuss current evidence regarding access barriers for the use of PCSK9 inhibitors.
The learning objectives of this program are:
- Discuss approaches to the evaluation of venous thromboembolism (VTE) in the outpatient setting
- Apply guideline-based recommendations toward the selection of pharmacotherapy for patients with VTE.
- Analyze the clinical efficacy and safety findings that support pharmacotherapy recommendations in VTE treatment guidelines
- Describe best practices for transitions of care (ToC) across healthcare settings among patients with DVT
- Develop strategies with patients and their caregivers to optimize treatment adherence and patient safety.
The learning objectives of this program are:
- Describe the clinical burden of anemia in patients with CKD
- Discuss the pathophysiology of anemia in CKD, including therapeutic targets
- Apply current assessment strategies to accurately diagnose patients with anemia and CKD based on clinical presentation
- Develop appropriate therapeutic regimens for patients with anemia and CKD based on goals of therapy